



Seashore Organic Medicine

SEASHORE ORGANIC MEDICINE INC.

**Form 2A/A
AMENDMENT TO LISTING STATEMENT No. 1**

Amendment Dated September 18, 2014

EXPLANATORY NOTE

Sechelt Organic Medicine Inc. (the “**Company**”) is filing this Amendment to Listing Statement No. 1 on Form 2A/A (the “**Amendment**”) to our Listing Statement dated August 8, 2014 and filed with the Canadian Securities Exchange on August 8, 2014, to amend the information appearing in such Listing Statement as detailed below.

AMENDMENT TO “SECTION 4. NARRATIVE DESCRIPTION OF THE BUSINESS: OPERATIONS”

The following paragraph located in “Section 4. Narrative Description of the Business”, under “Operations”, on page 13 of the Listing Statement of the Company is hereafter deleted:

“In the event that our application to become a Licensed Producer is approved, we have secured land in Sechelt, BC. The land has been assigned to the Company by the District of Sechelt and has been specifically designated as a “marijuana industrial production zone”. Designs for the Sechelt Facility have been completed and design plans are ready to be submitted to contractors for engineering and site preparation work (including electrical work, air handling, air conditioning, lighting, heating and cooling, wiring, drainage, water systems and security). Once “Ready to Build” approval is received from Health Canada, the Company anticipates a construction period of six months for the production facility. Pre-order of equipment will commence during the construction period, all of which are expected to be USA (Underwriters Laboratories of Canada) or CSA (Canadian Standards Association) approved. Approval from Health Canada as a Licensed Producer is hoped to be received after an inspection of the Sechelt Facility once it is built, and all the requirements for obtaining a license are met by the Company. Even though the site has been designated as a “marijuana industrial production zone” by the District of Sechelt, there is no guarantee that Health Canada will consider the site to be an appropriate site under the MMPR.”

The foregoing paragraph is hereafter replaced by the following:

“In the event that our application to become a Licensed Producer is approved, we hope to secure land in Sechelt, BC. We are currently in negotiations to acquire several properties in Sechelt. Designs for the Sechelt Facility have been completed and design plans are ready to be submitted to contractors for engineering and site preparation work (including electrical work, air handling, air conditioning, lighting, heating and cooling, wiring, drainage, water systems and security). Once a property has been acquired by the Company, and “Ready to Build” approval is received from Health Canada, the Company anticipates a construction period of six months for the production facility. Pre-order of equipment will commence during the construction period, all of which are expected to be USA (Underwriters Laboratories of Canada) or CSA (Canadian Standards Association) approved. Approval from Health Canada as a Licensed Producer is hoped to be received after an inspection of the Sechelt Facility once it is built, and all the requirements for obtaining a license are met by the Company. There is no guarantee that Health Canada will consider the acquired site to be an appropriate site under the MMPR.”

CERTIFICATE OF THE ISSUER

1. Pursuant to a resolution duly passed by its Board of Directors, Seashore Organic Medicine Inc. applied for the listing of the above mentioned securities on the CSE. The foregoing contains full, true and plain disclosure of all material information relating to Seashore Organic Medicine Inc. It contains no untrue statement of a material fact and does not omit to state a material fact that is required to be stated or that is necessary to prevent a statement that is made from being false or misleading in light of the circumstances in which it was made.
2. This Amendment No. 1 dated at Vancouver, British Columbia this 18th day of September 2014.

"Leonard Werden"

LEONARD WERDEN
Chief Executive Officer & Director

"Alexander Polevoy"

ALEXANDER POLEVOY
Chief Financial Officer & Director

"Vladlen Voskoboinikov"

VLADLEN VOSKOBAINIKOV
Director

"Jason Birmingham"

JASON BIRMINGHAM
Director